Abstract
The neuraminidase inhibitors (NAIs) oseltamivir (Tamiflu) and zanamivir (Relenza) have been implemented widely for treating patients with influenza: An estimated 18.3 million people worldwide received oseltamivir during the 2009–2010 H1N1 pandemic, according to the drug's manufacturer. Still, evidence supporting NAI use is relatively weak. Randomized trials of these drugs that involved relatively healthy patients showed only …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.